Molecular Screening for Cancer Treatment Optimization (MOSCATO 02)

Gustave Roussy

Status: Unknown

Conditions: Metastatic Solid Tumors (Any Localization)

Treatments: Procedure: Tumoral biopsy

Study type: Interventional

Funder types: Other

Identifiers

NCT01566019

2011/1755 (Other Identifier)

2011-A00841-40

Details and patient eligibility

About

The primary objective of the study is to use high throughput molecular analysis (CGH Array and sequencing) to treat patients with metastatic cancer with targeted therapeutics in order to improve the progression free survival compared to the previous treatment line.

The secondary objectives are to investigate clinical practical feasibility of such technics, to potentially improve the overall survival of patients and to describe molecular portrait of Phase 1 candidates.

Enrollment: 2,150 estimated patients

Sex: All

Ages: 6+ months old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Solid tumors ; Stade IV ; Local relapse or metastatic ; Uncurable
• Age > 6 months
• PS 0/1 or Lansky play scale >= 70%
• Minimum one treatment line, no limit in the prior number of treatment line
• Evaluable or measurable disease

Exclusion criteria

• Life expectancy < 3 months
• Carcinomatous meningitis
• Symptomatic or progressive radiologic brain metastasis for non-CNS tumors
• Polynuclear neutrophil < 1 x 10^9/L
• Platelets < 100 x 10^9/L
• Hemoglobin < 90 g/L
• ALT/AST > 2.5 N
• bilirubin > 1.5 N
• Creatinine >1.5 N
• Calcemia > ULN
• Phosphate > ULN
• Coagulation anomaly non-indicated for biopsy

Trial design

Primary purpose: Other

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

2,150 participants in 1 patient group

Patients with non curable metastatic cancer

Experimental group

Treatment:

Procedure: Tumoral biopsy